Michael J Sorich1, Andrew Rowland2, Christos S Karapetis3, Ashley M Hopkins2. 1. College of Medicine and Public Health, Flinders University, Adelaide, Australia. Electronic address: michael.sorich@flinders.edu.au. 2. College of Medicine and Public Health, Flinders University, Adelaide, Australia. 3. College of Medicine and Public Health, Flinders University, Adelaide, Australia; Department of Medical Oncology, Flinders Medical Centre, Adelaide, Australia.
Abstract
INTRODUCTION: There is substantial variability in survival and response outcomes for patients using immune checkpoint inhibitors (ICIs), and predictive markers are required to guide treatment decisions. A lung immune prognostic index (LIPI) was recently developed to predict ICI treatment outcomes and we aim to evaluate whether LIPI is predictive of survival and response for patients treated with atezolizumab for advanced NSCLC. METHODS: Pooled analysis was performed of patient-level data of four clinical trials of atezolizumab for NSCLC. Based on pre-treatment derived neutrophil-to-lymphocyte ratio greater than 3 and lactate dehydrogenase greater than the upper limit of normal, patients were assigned to one of three groups: good LIPI, 0 risk factors; intermediate LIPI, 1 risk factor; or poor LIPI, 2 risk factors. The primary outcome was overall survival (OS). RESULTS: In a pooled cohort of 1,489 patients treated with atezolizumab, the LIPI group was significantly associated with OS (p < 0.001), progression-free survival (p < 0.001), and response (p < 0.001). Median OS for good (n = 678), intermediate (n = 631), and poor (n = 180) LIPI groups was 18.4 months, 11.3 months, and 4.5 months, respectively. Association between LIPI and OS was consistently identified across a range of atezolizumab-treated subgroups. For docetaxel-treated patients (n = 687), LIPI was similarly associated with survival (p < 0.001) and response (p = 0.005). CONCLUSIONS: Pre-treatment LIPI is a convenient prognostic marker able to identify atezolizumab-treated patient groups with significantly different survival and response outcomes. However, LIPI is also a prognostic marker of survival and response for patients treated with chemotherapy; thus, it is not specifically predictive for ICI treatment.
INTRODUCTION: There is substantial variability in survival and response outcomes for patients using immune checkpoint inhibitors (ICIs), and predictive markers are required to guide treatment decisions. A lung immune prognostic index (LIPI) was recently developed to predict ICI treatment outcomes and we aim to evaluate whether LIPI is predictive of survival and response for patients treated with atezolizumab for advanced NSCLC. METHODS: Pooled analysis was performed of patient-level data of four clinical trials of atezolizumab for NSCLC. Based on pre-treatment derived neutrophil-to-lymphocyte ratio greater than 3 and lactate dehydrogenase greater than the upper limit of normal, patients were assigned to one of three groups: good LIPI, 0 risk factors; intermediate LIPI, 1 risk factor; or poor LIPI, 2 risk factors. The primary outcome was overall survival (OS). RESULTS: In a pooled cohort of 1,489 patients treated with atezolizumab, the LIPI group was significantly associated with OS (p < 0.001), progression-free survival (p < 0.001), and response (p < 0.001). Median OS for good (n = 678), intermediate (n = 631), and poor (n = 180) LIPI groups was 18.4 months, 11.3 months, and 4.5 months, respectively. Association between LIPI and OS was consistently identified across a range of atezolizumab-treated subgroups. For docetaxel-treated patients (n = 687), LIPI was similarly associated with survival (p < 0.001) and response (p = 0.005). CONCLUSIONS: Pre-treatment LIPI is a convenient prognostic marker able to identify atezolizumab-treated patient groups with significantly different survival and response outcomes. However, LIPI is also a prognostic marker of survival and response for patients treated with chemotherapy; thus, it is not specifically predictive for ICI treatment.
Authors: Juan Ruiz-Bañobre; María C Areses-Manrique; Joaquín Mosquera-Martínez; Alexandra Cortegoso; Francisco J Afonso-Afonso; Noemí de Dios-Álvarez; Natalia Fernández-Núñez; Cristina Azpitarte-Raposeiras; Margarita Amenedo; Lucía Santomé; José Luis Fírvida-Pérez; Rosario García-Campelo; Jorge García-González; Joaquín Casal-Rubio; Sergio Vázquez Journal: Transl Lung Cancer Res Date: 2019-12
Authors: Ahmad Y Abuhelwa; Ganessan Kichenadasse; Ross A McKinnon; Andrew Rowland; Ashley M Hopkins; Michael J Sorich Journal: Cancers (Basel) Date: 2021-04-21 Impact factor: 6.639
Authors: Claudia Marchetti; Marco D'Indinosante; Carolina Bottoni; Chiara Di Ilio; Stefano Di Berardino; Barbara Costantini; Angelo Minucci; Laura Vertechy; Giovanni Scambia; Anna Fagotti Journal: Sci Rep Date: 2021-05-27 Impact factor: 4.379
Authors: Boris Duchemann; Jordi Remon; Marie Naigeon; Lydie Cassard; Jean Mehdi Jouniaux; Lisa Boselli; Jonathan Grivel; Edouard Auclin; Aude Desnoyer; Benjamin Besse; Nathalie Chaput Journal: Transl Lung Cancer Res Date: 2021-06